SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Zora Neale Hurston — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientZora Neale Hurston
Date of birth1891-01-07
IdentifiersMRN HR-ML040-SYN-TD; SSN (made up) 000-40-6213
Document date1958-03-23
AuthorLorraine Abernathy-Osei, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review: blood pressure, echocardiogram and cardiology consultation. [S]

History of Present Illness

Ms. Hurston returns two weeks after intake and is seen the same day by Dr. Okafor-Whitfield of cardiology after her echocardiogram this morning. The 24-hour ambulatory recording before her first doses averaged 158/96 mmHg (daytime 163/99, night 149/90), with no fall in pressure at night, which confirms stage 2 hypertension. She started chlorthalidone 12.5 mg and amlodipine 5 mg the next morning; her home readings over the past week average 146/88. The morning headaches have gone. She is still breathless on one flight of stairs and her ankles swell a little by evening. She has had no lightheadedness, cramps or palpitations. The echocardiogram shows a preserved ejection fraction with thick heart walls and stiff filling. She met the community health worker last week: her SNAP application is in, and a SHINE counselor will see her on Thursday about drug coverage. [S]

ElementDetail
Ambulatory blood pressure24-hour mean 158/96 mmHg; daytime 163/99; night 149/90 (non-dipping)
Home blood pressure on treatmentAverage 146/88 mmHg over seven days
SymptomsHeadaches gone; breathless on one flight of stairs; mild evening ankle swelling
EchocardiogramEjection fraction 62%; concentric left ventricular hypertrophy; grade II diastolic dysfunction
KCCQ-1254

Review of Systems

SystemResultFinding
CardiovascularPositiveBreathless on one flight of stairs; mild evening ankle swelling; no chest pain, palpitations, orthopnea or night breathlessness
NeurologicalNegativeHeadaches resolved; no weakness, numbness, speech or vision change
GenitourinaryNegativePassing more urine in the mornings; no burning
MusculoskeletalNegativeNo cramps

4 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Amlodipine 5 mg oral tablet, one tablet every morningOne tablet every morningOral route1958-03-09activeS
Chlorthalidone 25 mg oral tablet, one-half tablet (12.5 mg) every morningOne-half tablet every morningOral route1958-03-09activeS
Dapagliflozin 10 mg oral tablet, one tablet daily; pause on days of vomiting, diarrhea or not eating or drinkingOne tablet daily, with sick-day rulesOral route1958-03-23activeS
Atorvastatin 20 mg oral tablet, one tablet dailyOne tablet dailyOral route1958-03-23activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1958-03-23Body height165cmS
1958-03-23Body weight83.4kgS
1958-03-23Body mass index (BMI) [Ratio]30.6kg/m2S
1958-03-23Systolic blood pressure150mm[Hg]S
1958-03-23Diastolic blood pressure90mm[Hg]S
1958-03-23Heart rate78/minS
1958-03-23Respiratory rate16/minS
1958-03-23Body temperature36.6CelS
1958-03-23Oxygen saturation in Arterial blood by Pulse oximetry97%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1958-03-23Sodium [Moles/volume] in Serum or Plasma138mmol/L135-145 mmol/LNormalS
1958-03-23Potassium [Moles/volume] in Serum or Plasma3.6mmol/L3.5-5.1 mmol/LNormalS
1958-03-23Creatinine [Mass/volume] in Serum or Plasma0.94mg/dL0.59-1.04 mg/dLNormalS
1958-03-23Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1953)/1.73 sq M67mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1958-03-23Glucose [Mass/volume] in Serum or Plasma98mg/dL70-99 mg/dLNormalS
1958-03-23Magnesium [Mass/volume] in Serum or Plasma1.9mg/dL1.6-2.6 mg/dLNormalS
1958-03-23Left ventricular Ejection fraction62%50-70%NormalS
1958-03-23Left atrial End-systolic volume (by US.2D+Calculated by biplane method of disks)/Body surface area38mL/m2<=34 mL/m²HighS
1958-03-23Heart valve E velocity/Annulus E wave by US15{ratio}<=14HighS
1958-03-23Overall summary score [KCCQ-12]54{score}S

Physical Exam

Vital signs recorded on 1958-03-23; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 150/90, pulse 78; weight 83.4 kg, down 0.8 kg
NeckJugular venous pressure not raised; no carotid bruits
CardiovascularRegular rhythm; sustained apical impulse; S4; no murmur
RespiratoryClear
ExtremitiesTrace ankle edema

Problems

ProblemClinical statusVerificationCodeProvenance
Very high blood pressure at intake (178/104 and 174/102 mmHg) with morning headaches for two months, without signs of a hypertensive emergency; not previously diagnosed; ambulatory monitoring to confirmresolvedconfirmed R03.0S — Synthetic presenting problem, resolved when ambulatory monitoring and the echocardiogram established the diagnosis at the second visit. Not a claim about her real blood pressure.
Breathlessness on exertion for three months (walking to the school, carrying groceries) with mild ankle swelling by evening; cause to be determinedresolvedconfirmed R06.09S — Synthetic presenting problem, resolved into the heart failure diagnosis at the second visit.
Hypertensive heart disease with heart failure: stage 2 hypertension confirmed by 24-hour ambulatory monitoring (mean 158/96 mmHg, non-dipping at night), with concentric left ventricular hypertrophy on ECG and echocardiogram; synthetic modern episode linked to the hypertensive heart disease recorded as her cause of deathactiveconfirmed I11.0S — Synthetic modern diagnosis made at the second visit; the 1960 cause of death remains D.
Heart failure with preserved ejection fraction (ejection fraction 62%), NYHA class II, with grade II diastolic dysfunction and an enlarged left atriumactiveconfirmed I50.32S — Synthetic modern diagnosis confirmed by echocardiogram and cardiology at the second visit.
Food insecurity: food runs short at the end of most months (Hunger Vital Sign positive)activeconfirmed Z59.41S — Synthetic social need anchored to her documented poverty.
Low and irregular income from substitute teaching and newspaper writing, with Original Medicare but no drug coverage; medicine costs a barrieractiveconfirmed Z59.6S — Synthetic social need anchored to her documented low income in the 1950s.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
ExaminationBlood pressure in the clinic (seated, average of two readings, large cuff)Every visitCompleted today150/90 mmHg
ExaminationOut-of-office blood pressure (ambulatory at diagnosis; home readings when treatment changes)At diagnosis and with each treatment changeCompleted todayAmbulatory 24-hour mean 158/96 (non-dipping) before treatment; home average 146/88 on treatment
ExaminationWeight, volume status (jugular venous pressure, edema, lungs) and NYHA classEvery visitCompleted today83.4 kg; jugular venous pressure not raised; trace ankle edema; lungs clear; NYHA II
LaboratoryMetabolic panel (sodium, potassium, creatinine and eGFR) and magnesiumOne to two weeks after starting or changing a diuretic, SGLT2 inhibitor or MRA; then every three to six monthsCompleted todayTwo weeks after chlorthalidone: sodium 138, potassium 3.6, creatinine 0.94 mg/dL (eGFR 67), magnesium 1.9
ImagingECG and echocardiogramAt diagnosis; repeat only with unexplained clinical changeCompleted todayECG at intake: left ventricular hypertrophy, sinus rhythm. Echocardiogram today: ejection fraction 62%, left atrial volume index 38 mL/m2, E/e' 15, concentric hypertrophy
SurveyKCCQ-12 heart failure health statusAt diagnosis, then every three to six monthsCompleted today54 at diagnosis
LaboratoryLipid panelFour to twelve weeks after starting a statin; then yearlyOrderedLDL 132 mg/dL at intake; atorvastatin started today; panel due in four to twelve weeks
LaboratoryUrine albumin-to-creatinine ratioYearlyUp to date22 mg/g at intake
LaboratoryHemoglobin A1cYearlyUp to date5.6% at intake
SurveyDepression screen (PHQ-2, then PHQ-9 if positive)YearlyUp to datePHQ-2 1 at intake
ExaminationEye examination for hypertensive retinopathyYearlyUp to dateArteriolar narrowing and nicking without hemorrhage at intake; dilated examination to be arranged
Self-managementSelf-care: daily weights, less salt, sick-day rules and the BE FAST stroke signsEvery visitCompleted todayScale at home; written weight plan; sick-day rules for dapagliflozin; BE FAST card reviewed
Medication safetyMedicine costs and coverage (generics, 90-day fills, patient assistance, Extra Help, Medicare Savings Program)Every visitCompleted todayGenerics in 90-day fills; patient assistance for dapagliflozin; SHINE appointment this week
Self-managementFood accessEvery visitCompleted todaySNAP application submitted with the community health worker
ReferralCardiology consultationAt diagnosisCompleted todaySeen by Dr. Okafor-Whitfield today

Goal progress:

Immunizations given today: Pneumococcal conjugate vaccine PCV20 [S]

Guideline basis: 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults (2025); 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure (2022); 2023 ACC Expert Consensus Decision Pathway on Management of Heart Failure With Preserved Ejection Fraction (2023); CMID: Clinical Monitoring Intelligence Database, hypertension and heart failure monographs (2026); Signs and Symptoms of Stroke (2026); Help with drug costs (Extra Help) (2026); SHINE (Serving Health Insurance Needs of Elders), Florida's State Health Insurance Assistance Program (2026)

Follow-up: Two-week review with a metabolic panel. Call for lightheadedness, a weight gain beyond the plan, or breathlessness at rest; call 911 for any BE FAST sign or chest pain. Next scheduled visit 1958-04-06: two-week review after dapagliflozin: metabolic panel, blood pressure and potassium, and benefits applications. [S]